This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as a Hybrid Event from September 20-30, 2021
Live In-Person Experience Delivered September 20-23Boston Convention and Exhibition Center
Menu
Book
keyboard_arrow_right

CONFERENCE DAY ONE - EST/EDT (Eastern Daylight, GMT-4)

keyboard_arrow_leftSearch & Filter
search

CONFERENCE DAY ONE - EST/EDT (Eastern Daylight, GMT-4)

search
7:00am - 8:00am60 mins
Coffee & Registration
    8:00am - 8:15am15 mins
    Chairperson’s Opening remarks
    • Muthiah (Mano) Manoharan, PhD - Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals, Inc.
    Plenary Session
    8:15am - 9:00am45 mins
    Joint Plenary Session
    RNAi Therapeutics: Past, Present, and (Mostly) Future
    • John Maraganore, PhD - Chief Executive Officer, Alnylam Pharmaceuticals, Inc
    9:00am - 9:45am45 mins
    Joint Plenary Session
    My Long Road from the 2’-5’ Oligos to the mRNA Vaccine
    • Katalin Karikó, PhD - Senior Vice President RNA Protein Replacement Therapy, BioNTech
    9:45am - 10:25am40 mins
    Morning Coffee and Networking
      10:25am - 10:30am5 mins
      Cell Therapy
      Chairperson's Opening Remarks
      • Shashi Murthy, PhD - Founder & CTO, Flaskworks
      10:25am - 10:30am5 mins
      Gene Edited Ex Vivo Cell Therapy / In Vivo Gene Therapy
      Chairperson's Opening Remarks
      • Chris Gemmiti, Ph.D. - Executive Director of Technical Operations; Head of Early Stage CMC and Product Launch Programs, CRISPR Therapeutics
      10:25am - 10:30am5 mins
      In Vivo Gene Therapy
      Chairperson's Opening Remarks
      • Jorge Santiago-Ortiz, Ph.D. - Director, Process Development, BioCentriq, USA
      10:30am - 11:00am30 mins
      Cell Therapy
      Please move to another track
        10:30am - 11:00am30 mins
        Gene Edited Ex Vivo Cell Therapy / In Vivo Gene Therapy
        Scale Up & Manufacture of CRISPR Gene Edited Hematopoietic Stem Cell (eHSC) Therapies for AML
        • Sadik H. Kassim - Chief Technology Officer, Vor Biopharma
        10:30am - 11:00am30 mins
        In Vivo Gene Therapy
        A Simple and Robust AAV Manufacturing System to Achieve High Titer And Quality Gene Therapy Vector
        • Shenjiang (Shawn) Liu - President & CEO, Avirmax Inc.
        11:00am - 11:30am30 mins
        Cell Therapy
        Risk Based Approaches to Comparability
        • Silky Kamdar - Manager, BMS
        11:00am - 11:30am30 mins
        Gene Edited Ex Vivo Cell Therapy / In Vivo Gene Therapy
        Leveraging Platform Technologies for Gene Therapies
        • Jessica Carmen, PhD - US Business Development Adviser, Oxford Biomedica, USA
        11:00am - 11:30am30 mins
        In Vivo Gene Therapy
        Optimisation of AAV Production: Transfection Matters
        • Hélène Trottin - Senior Technical Specialist, Process Sciences, Pharmaron
        11:30am - 11:50am20 mins
        Cell Therapy
        Engineering of hemopoietic stem cells on the CliniMACS Prodigy®
        • Eleni Papanikolaou - Manager Hemapoietic Stem Cell Gene Therapy and Graft Engineering, Miltenyi Biotec, Germany
        11:30am - 11:50am20 mins
        In Vivo Gene Therapy
        Design, Manufacturing and Analytics of New AAV Reference Materials – A Case Study
        • Jeffrey Hung - Chief Commercial Officer, Vigene Biosciences, Inc., USA
        11:50am - 12:05pm15 mins
        Cell Therapy
        Custom Assay Development on the Accellix Automated Flow Cytometry Platform
        • Amanda Trent - Director of Assay Development, Accellix, Inc., USA
        11:50am - 12:05pm15 mins
        In Vivo Gene Therapy
        Mass Spectrometry Support for HCP Elisa In AAV Gene Therapy
        • Andrew Hanneman - Scientific Advisor, Biologics Testing, Charles River Massachusetts, Biologics Division, USA
        12:05pm - 1:30pm85 mins
        Lunch & Learns & Networking
        • Breanna Borys - PhD Candidate, PBS Biotech, Inc., USA
        • Sunghoon Jung PhD - Senior Director of Bioprocess Research & Development, , PBS Biotech, Inc., USA
        • Rajeshwar Chinnawar - Senior R&D Engineer, Pall Corporation, USA
        1:30pm - 2:00pm30 mins
        Cell Therapy
        Strategies for Maximizing MSC-EV Productivity and Lot Size
        • Jon A. Rowley, Ph.D. - Founder & Chief Product Officer, RoosterBio Inc.
        1:30pm - 2:00pm30 mins
        Gene Edited Ex Vivo Cell Therapy / In Vivo Gene Therapy
        High Throughput Upstream Processing and Quality Analysis via Microfluidic Capillary Electrophoresis
        • James Geiger, PhD - Field Application Scientist, PerkinElmer, USA
        2:00pm - 2:30pm30 mins
        Cell Therapy
        iPSC Processes: Road to Automation and Closed Systems
        • Cenk Sumen - Chief Technology Officer, Stemson Therapeutics
        2:00pm - 2:30pm30 mins
        Gene Edited Ex Vivo Cell Therapy / In Vivo Gene Therapy
        bluebird bio Supply Chain Strategy Case Study
        • Roy Sorek - Director, Quality Assurance, bluebird bio
        2:30pm - 3:00pm30 mins
        Cell Therapy
        Scalable and Customizable Solutions for Cell and Gene Therapy Manufacturing
        • Nithya Jesuraj - Product Manager, CGT, Bio-Techne, USA
        2:30pm - 2:50pm20 mins
        Gene Edited Ex Vivo Cell Therapy / In Vivo Gene Therapy
        Big Solutions Come in Small Packages: Expanding Sterile Connection Technology to Small-Format Product or Process Fluid Volume Transfer Applications
        • Jayanthi Grebin - Sr. Business Development Manager CGT, CPC - Colder Products Coompany
        2:50pm - 3:10pm20 mins
        Gene Edited Ex Vivo Cell Therapy / In Vivo Gene Therapy
        Evaluation of novel affinity resin with alkali stable ligand for AAV viral vectors
        • Nagendra Singh - Senior Scientist, Downstream Process Development, Catalent Cell & Gene Therapy, USA
        3:10pm - 4:00pm50 mins
        Refreshment Break in the Poster & Exhibit Hall
          4:00pm - 4:20pm20 mins
          Cell Therapy
          Selection & Management of Suppliers and Contract Service Providers
          • Ruti Goldberg - Compliance and Methods Validations Manager, Pluristem Therapeutics
          4:00pm - 4:30pm30 mins
          Gene Edited Ex Vivo Cell Therapy
          Manufacturing process optimization during early- and late-stage development
          • Ali Mohamed - VP, CMC, Immatics
          4:00pm - 4:30pm30 mins
          In Vivo Gene Therapy
          Developing an Integrated Manufacturing Process and Platform to Increase Speed to Clinic
          • Alex Meola - Scientist II, Downstream Process Development, Homology Medicines
          4:20pm - 4:40pm20 mins
          Cell Therapy
          Cell Therapy Raw Materials Customization
          • Lili Belcastro - Principal Scientist, Cell Therapy Raw Materials, Bristol Myers Squibb
          4:30pm - 5:00pm30 mins
          Gene Edited Ex Vivo Cell Therapy
          PANEL: Let’s Settle the Debate – Can Auto and Allo Therapies Co-Exist
          • Jon A. Rowley, Ph.D. - Founder & Chief Product Officer, RoosterBio Inc.
          • Ali Mohamed - VP, CMC, Immatics
          • Armon Sharei - Chief Executive Officer & Founder, SQZ Biotechnologies, USA
          • Cenk Sumen - Chief Technology Officer, Stemson Therapeutics
          4:30pm - 5:00pm30 mins
          In Vivo Gene Therapy
          Mechanistic Modelling for the Production of Recombinant Adeno-Associated Virus via Triple Transfection of HEK293 Cells
          • Tam Nguyen - PhD Candidate, Massachusetts Institute of Technology, USA
          4:40pm - 5:00pm20 mins
          Cell Therapy
          Fitting Product to Process: Raw Materials Customization for Cell Therapy Manufacturing Success
          • Raymond Luke - Associate Director, MS&T, Adaptimmune (pending final confirmation)
          5:00pm - 5:30pm30 mins
          Cell Therapy
          Quality by Design (QbD) for Adeno-Associated Virus (AAV) Products
          • Parth Trivedi M.S. - Team Manager, Pall Corporation, USA
          5:00pm - 5:30pm30 mins
          Gene Edited Ex Vivo Cell Therapy
          Quality by Design (QbD) for Adeno-Associated Virus (AAV) Products
          • Parth Trivedi M.S. - Team Manager, Pall Corporation, USA
          5:00pm - 5:30pm30 mins
          In Vivo Gene Therapy
          Quality by Design (QbD) for Adeno-Associated Virus (AAV) Products
          • Parth Trivedi M.S. - Team Manager, Pall Corporation, USA
          5:30pm - 6:30pm60 mins
          Grand Opening of the Poster & Exhibit Hall and Cocktail Reception
            6:30pm - 7:00pm30 mins
            End of Day One
              PRE-CONFERENCE DAY
              NextCONFERENCE DAY TWO
              Filter
              Streams
              Formats
              Choose Day